SecBot SecBot
PRESS-RELEASE ·Filed Mar 23, 2026

ABVX

Abivax
MIXED
Impact 6/10
Horizonmonths Processed7mo ago WireGlobeNewswire
Press release · Earnings
Actionable Insight ◆ Mixed

Traders should monitor late Q2 2026 for topline Phase 3 data from the ABTECT-UC trial, which will be a major catalyst. The strong cash runway into Q4 2027 supports continued development, but profitability remains distant.

DirectionMixed
Confidencehigh
Horizonmonths

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$110.17
T+0 close · Mar 23, 2026 · via day close
Latest settled
−10.00%
T+60 · $99.15
Vs SPY
−24.33%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Mar 24 $110.17entry
  2. T+1 · 8mo ago +0.48%α −0.09% · $110.70
  3. T+5 · 8mo ago +1.07%α +1.49% · $111.35
  4. T+20 · 7mo ago +5.28%α −3.62% · $115.99
  5. T+60 · 5mo ago −10.00%α −24.33% · $99.15
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Abivax reported full-year 2025 financial results with a net loss of €336.1 million, driven by higher R&D and G&A expenses, but strengthened its balance sheet with €530.4 million in cash after a $700.3 million public offering. The company remains on track to report topline Phase 3 data for obefazimod in ulcerative colitis in late Q2 2026, and appointed a new Chief Commercial Officer to prepare for potential commercialization.

Key Financial Metrics

Revenue
$4.6M
-62.9% YoY
EPS
$-1.34

Key Facts

  • Net loss widened to €336.1 million in 2025 from €176.2 million in 2024
  • Cash, cash equivalents, and short-term investments totaled €530.4 million as of December 31, 2025
  • Raised $700.3 million (€597.2 million) in a public offering in July 2025
  • DSMB found no new safety signals in the Phase 3 ABTECT-UC trial; topline results expected late Q2 2026
  • Appointed Michael Nesrallah as Chief Commercial Officer to lead launch preparation for obefazimod

Financial Impact

Cash position increased by €372.5 million net of operations and financing; operating loss increased by €73.1 million year-over-year

cashnet_lossoperating_lossr_and_d_expenseg_and_a_expense

Risk Factors

  • Clinical trial results may not meet endpoints despite favorable safety data
  • High cash burn rate: €161.1 million used in operations in 2025
  • Dilution from the $700.3 million public offering may pressure shares if results disappoint

Market Snapshot

Exchange
OTC

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3260837

Track record

10 reports on ABVX

Performance horizon

4 of 5 bullish or bearish reports moved the stock their way by T+5. Best: +33.05% at T+60 after the Jul 2, 2026 report. 5 of 5 went positive at some point.

Filters
  1. Nov 16, 2026today SC 13G/A Neutral 2/10 Entry $83.40 Now $87.58 +5.01% settles Nov 24
  2. Oct 30, 202617d ago Institutional Cluster Neutral 2/10 Entry $86.59 to $85.73 Now $87.58 +1.14% ▼ −0.99% +1.71% vs SPY
  3. Aug 6, 202614w ago Institutional Cluster Mixed 5/10 Entry $130.00 to $121.45 Now $87.58 −32.63% ▼ −6.58% −7.79% vs SPY
  4. Jul 2, 202619w ago 6-K Bearish 6/10 Entry $144.65 to $140.74 Now $87.58 +39.45% ▲ +2.70% +3.63% vs SPY
  5. Jul 2, 202619w ago 424B5 Bearish 6/10 Entry $144.65 to $140.74 Now $87.58 +39.45% ▲ +2.70% +3.63% vs SPY
  6. Jul 1, 202619w ago Press Release Bearish 6/10 Entry $132.56 to $142.17 Now $87.58 +33.93% ▼ −7.25% −6.99% vs SPY
  7. Jun 29, 202620w ago 6-K Bullish 7/10 Entry $133.26 to $143.99 Now $87.58 −34.28% ▲ +8.05% +7.45% vs SPY
  8. Jun 29, 202620w ago Press Release Bullish 7/10 Entry $133.26 to $143.99 Now $87.58 −34.28% ▲ +8.05% +7.45% vs SPY
  9. May 22, 202625w ago Press Release Neutral 5/10 Entry $126.41 to $129.69 Now $87.58 −30.72% ▲ +2.59% +1.51% vs SPY
  10. Mar 23, 202634w ago Press Release Mixed 6/10 Viewing Entry $110.17 to $111.35 Now $87.58 −20.50% ▲ +1.07% +1.49% vs SPY
Showing 10 of 10

US Market Status

Market Closed · Opens Wed (13h 13m)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Mar 23, 2026